Related Experiment Video
Updated: Jul 24, 2025
10:38
A Cognitive Paradigm to Investigate Interference in Working Memory by Distractions and Interruptions
Published on: July 16, 2015
13.7K
Cognitive Interventions for Neurodegenerative Disease
Jason W Krellman1, Giulia Mercuri2
1Department of Neurology, Columbia University Irving Medical Center, 710 West 168Th Street, New York, NY, 10032-3784, USA. jk3878@cumc.columbia.edu.
Current Neurology and Neuroscience Reports
|July 10, 2023
Summary
Non-pharmacological interventions for Alzheimer's disease (AD) and Parkinson's disease (PD) show varied results. Cognitive rehabilitation (CR) is most promising, requiring flexible, individualized approaches for progressive neurodegenerative diseases.
Area of Science:
- Neuroscience
- Gerontology
- Cognitive Psychology
Background:
- Alzheimer's disease (AD) and Parkinson's disease (PD) are progressive neurodegenerative disorders.
- Cognitive decline is a significant symptom impacting quality of life in AD and PD patients.
Purpose of the Study:
- To critically review recent research on non-pharmacological interventions for cognitive enhancement in AD and PD.
- To evaluate the efficacy and limitations of different intervention categories.
Main Methods:
- Categorization of interventions into cognitive stimulation (CS), cognitive training (CT), and cognitive rehabilitation (CR).
- Analysis of research findings on the benefits, durability, and real-world utility of each category.
Main Results:
- Cognitive stimulation (CS) offers temporary, non-specific benefits.
- Cognitive training (CT) improves specific cognitive functions but lacks durable, real-world application.
- Cognitive rehabilitation (CR) is the most promising due to its holistic and flexible nature, though challenging to study rigorously.
Conclusions:
- Optimal cognitive intervention for AD and PD requires a multifaceted, individualized approach.
- Cognitive rehabilitation (CR) necessitates dynamic, long-term strategies tailored to the patient's evolving needs.
- Clinicians should select interventions based on patient tolerance, needs, and goals for progressive neurodegenerative diseases.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
159
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
159
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
01:30Cognitive Development During Adulthood
160
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
160
01:26Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
01:30Dementia
141
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
141
01:17Cognitivism
1.4K
Cognitive psychology emerged as a significant field in the mid-20th century. It focused on understanding humans' internal mental processes. This approach emphasizes how people perceive, remember, think, and solve problems—elements critical to human cognition.
Previously dominated by behaviorism, which prioritized observable behaviors and largely ignored mental processes, psychology transformed in the 1950s. Cognitive psychologists argue that understanding how we think and process...
Previously dominated by behaviorism, which prioritized observable behaviors and largely ignored mental processes, psychology transformed in the 1950s. Cognitive psychologists argue that understanding how we think and process...
1.4K